



For Immediate Release

## **GREATER BAY AREA INTERNATIONAL CLINICAL TRIAL INSTITUTE AND AMGEN COLLABORATE TO ADVANCE HEALTHCARE INNOVATION AND IMPROVE PATIENT CARE IN HONG KONG**

*Collaboration focuses on talent development, scientific exchange and the use of high-quality evidence to enhance care delivery.*

**Hong Kong, July 8, 2026** – The Greater Bay Area International Clinical Trial Institute (“GBAICTI”) and biotechnology company Amgen today announced their collaboration through the signing of a Memorandum of Understanding to strengthen capabilities and improve patient outcomes in Hong Kong and the wider Greater Bay Area (“GBA”). Hong Kong’s strong clinical, academic and healthcare environment positions it well to support cross-boundary collaboration in biomedical innovation across the GBA. With a population of over 88 million across the GBA, the region provides opportunities for clinical research, real-world evidence generation and the development of more effective, accessible and patient-centered healthcare solutions.

The strategic collaboration will support the GBAICTI’s and Hong Kong’s broader commitment to advancing research and development, reinforcing its position as an international health and medical innovation hub.

Amgen draws on more than four decades of experience in biotechnology innovation and a deep commitment to applying science in ways that improve patient care. Through the collaboration, Amgen will contribute its scientific expertise and global experience in clinical research and real-world evidence alongside GBAICTI’s strong clinical and academic network in Hong Kong and the GBA.

As part of the collaboration, GBAICTI and Amgen will focus on scientific exchange, talent development and the use of high-quality real-world evidence to enhance care delivery. This includes advancing key initiatives in clinical research innovation, real-world evidence generation, implementation science and capability building across Hong Kong and the GBA, supporting more efficient and effective care pathways.

The collaboration will also engage local tertiary institutions to develop training programs, supporting talent development and fostering the next generation of clinical research expertise in the region.

**Professor Bernard Cheung, chief executive officer at GBAICTI** said: “Our collaboration with Amgen reflects our commitment to building a high-quality, connected research ecosystem that links Hong Kong with international partners. By enabling collaboration and aligning capabilities, we aim to enhance research excellence, improve patient care and contribute to the long-term development of healthcare and biomedical innovation.”



“At Amgen, we believe innovation has the greatest impact when science and evidence can be applied in practical ways to improve patient care,” said **Kara Cheung, general manager, Hong Kong at Amgen**. “Through this collaboration, we look forward to contributing our scientific expertise and global experience in clinical research and real-world evidence while working closely with partners across Hong Kong's healthcare ecosystem to improve outcomes for patients.”

The initial phase of the collaboration will prioritize initiatives in early research, real-world evidence and capability development. This includes exploring innovative study models, generating decision-grade evidence, accelerating its translation into clinical practice and strengthening expertise in evidence generation and biostatistics.

###

### **About the Greater Bay Area International Clinical Trial Institute**

The Greater Bay Area International Clinical Trial Institute (GBAICTI) is a unified platform for clinical innovation, bringing together Hong Kong's public and private medical resources to support research institutions across the region. Located in the Hong Kong Park of the Hetao Shenzhen–Hong Kong Science and Technology Innovation Co-operation Zone, GBAICTI provides a one-stop support platform for clinical trials and plays a central role in strengthening the Greater Bay Area's position as a world-class hub for research.

Through seamless cross-border collaboration, streamlined processes, real-world data application, and talent development, we help accelerate the development of medicines. Working closely with the Greater Bay Area International Clinical Trials Center in Shenzhen, GBAICTI leverages the complementary strengths of the “one institute, one center” model to coordinate multi-centre trials that meet national and international standards.

To learn more, please visit: <https://gbaicti.hk/>

### **About Amgen**

Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines.

More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, inflammatory conditions, rare diseases, heart disease and obesity and obesity-related conditions.



Amgen has been [consistently recognized](#) for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

For more information, visit [Amgen.com](https://www.amgen.com) and follow Amgen on [X](#), [LinkedIn](#), [Instagram](#), [YouTube](#), [Facebook](#), [TikTok](#) and [Threads](#).

### **Media contact**

#### Amgen

Elisabelle Aruldoss, Corporate Affairs Manager

earuldos@amgen.com

+65 9137 8439

#### GBAICTI

Samantha Wong, Director (Global Communications & Engagement)

samantha.wong@gbaicti.hk

+852 5366 1368